Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02898259
Title Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center

B-cell lymphoma


Ixazomib + Lenalidomide + Rituximab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.